Cart
sales@molnova.com
Tisotumab
CAS No. 1418628-81-5
Tisotumab( —— )
Catalog No. M36872 CAS No. 1418628-81-5
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targeting tissue factor (TF), utilized in antibody-conjugating drugs for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 655 | In Stock |
|
| 10MG | 1017 | In Stock |
|
| 25MG | 1691 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTisotumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targeting tissue factor (TF), utilized in antibody-conjugating drugs for cancer research.
-
DescriptionTisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1418628-81-5
-
Formula WeightApproximately 44.66 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22(5):609-619.?
molnova catalog
related products
-
OsMundacetone
OsMundacetone is a natual product isolated from Rhizoma osmundae.
-
3-Guanidinopropionic...
3-Guanidinopropionic acid is a creatine analog that alters skeletal muscle energy expenditure.?It reduces cellular ATP creatine and phosphocreatine levels and stimulates AMP-activated protein kinase (AMPK) activating PPARγ coactivator 1α (PGC-1α).
-
Ulixertinib
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
